Joseph A. Piechocki
Consumer Safety Officer
ORA Division of Pharmaceutical Quality Operations
Detail-oriented international investigator with inspections across India, Jordan, and the US — known for physically checking waste disposal areas for destroyed records and deep-diving into computer system audit trails.
Inspection Approach
How Joseph Inspects
Piechocki brings a forensic approach to CGMP inspections, with a particular talent for uncovering data integrity failures through unconventional investigation methods. At Granules India, he physically inspected waste disposal areas and discovered torn cGMP records in 15+ plastic waste bags — a finding that transformed the inspection into a major data integrity case resulting in a February 2025 warning letter.
His technical depth extends to computer system controls. At Cipla's Verna facility, he identified user access issues in PC Visual and FactoryTalk View systems, and his review of analytical methods consistently reveals gaps in method transfer documentation and validation. He cross-references batch records, logbooks, and electronic systems to identify discrepancies that point to broader quality system failures.
Piechocki frequently co-investigates with Tamil Arasu, Pratik S. Upadhyay, and Eileen A. Liu — creating combined teams that cover laboratory controls, data integrity, and manufacturing quality simultaneously. His inspection at Amman Pharmaceutical Industries in Jordan, where he documented several hundred manual interventions per batch during aseptic manufacturing, led to a warning letter and Import Alert 66-40.
Citation Patterns
Top Focus Areas
Inspection History
Notable Inspections
Granules India Limited
- Torn cGMP records found in 15+ plastic waste bags — systematic document destruction
- Unknown chromatographic peaks several times higher than known API peaks not identified or investigated
- Damaged HEPA filters and microbial contamination in air supply ducts
- Cross-contamination risk between products manufactured on shared equipment
- 26-page Form 483 with 6 observations — warning letter issued February 2025
Cipla Limited (Verna, Goa)
- Computer system user access issues in PC Visual and FactoryTalk View systems
- Unvalidated/unverified test methods for drug products and APIs
- Media fill failure with inconclusive investigation — root cause not scientifically established
- Deficiencies in aseptic area environmental controls
Amman Pharmaceutical Industries
- Several hundred manual interventions per batch during aseptic manufacturing in July 2023
- Aseptic connections performed with breaches in technique under unacceptable air classifications
- Firm placed on Import Alert 66-40 — warning letter issued February 2024
Laurus Synthesis Private Limited
- Inadequate investigations of unexpected occurrences during manufacturing
- Incomplete batch production records with missing documentation
- Equipment not maintained or cleaned to prevent contamination
- Data integrity concerns — FDA directed Laurus to ensure accuracy and integrity of data
Somerset Therapeutics Private Limited
- Manufacturing compliance deficiencies at finished dosage form facility
- Co-investigated with Eileen A. Liu
Pre-Inspection Preparation
How to Prepare
- 1 Ensure all cGMP records are intact and accounted for — Piechocki physically inspects waste disposal areas for destroyed documents.
- 2 Validate all analytical methods with complete documentation of method transfers between laboratories.
- 3 Review computer system user access controls, audit trails, and electronic data integrity for systems like FactoryTalk, ELN, and HPLC software.
- 4 Ensure cleaning validation protocols are current and scientifically justified, especially for shared manufacturing equipment.
- 5 Verify all investigations have documented, scientifically sound root cause analyses — not just "most probable cause" statements.
- 6 Confirm CAPA effectiveness checks are completed and documented with evidence of recurrence prevention.
- 7 Ensure stability data is available before releasing reworked or reprocessed batches.
- 8 Review equipment maintenance records and HEPA filter integrity documentation — damaged filters are a critical finding.
- 9 Prepare complete distribution records with full batch traceability for all manufactured products.
- 10 Minimise manual interventions during aseptic manufacturing — several hundred per batch was cited as a critical observation at Amman Pharmaceutical.
- 11 Verify training records demonstrate effectiveness, not just completion of training modules.
Commonly Cited Regulations
Top CFR Citations
Frequently Paired With
Co-Investigators
Geographic Reach
Download Joseph A. Piechocki — FDA Investigator Profile
Enter your details once to unlock all Audit Hub resources. All future downloads are instant.
Leucine is the first AI-native platform built for pharmaceutical manufacturing. It unifies quality management, regulatory compliance, and production operations into one intelligent system that powers your entire drug manufacturing lifecycle from raw materials to patient delivery.
